Dr Tristan Vaughan, a senior director of lead generation, was recognised in the list completed by PharmaVOICE 100 for the positive contributions he has made to MedImmune, his communities and the motivation he has provided to colleagues and peers. “Dr Vaughan has continually driven improvements in the technologies that have successfully delivered drugs that make a meaningful difference to patients. This is what motivates him, not position, salary, or recognition,” said the magazine.
“Dr Vaughan exemplifies the spirit of innovation that is central to MedImmune’s mission and we are very proud that his work has been recognised by PharmaVOICE,” said Dr Jane Osbourn, Site Leader, Cambridge, UK and Vice President of Research and Development. “Dr Vaughan demonstrates the inspiring dedication of our scientists to delivering life-changing products to help patients with unmet medical needs.”
Dr. Vaughan has been central to the development of two life-changing medications, including the first fully human antibody to reach the market as well as the first new treatment option for patients with systemic lupus erythematosus in more than 50 years. He currently leads a team of more than 80 working on refining the technologies that have successfully delivered drugs that make a meaningful difference to patients.
Says Roz Bird, Granta Park’s Marketing and Asset Manager: “We are delighted that Dr Vaughan has been recognised in this way, his success will undoubtedly inspire many other people working here at Granta Park in our special high-tech community.”
Dr Gail Wasserman from MedImmune in the US was also recognised by the list. Dr. Wasserman’s pioneering development work contributed to the introduction of the first monoclonal antibody approved by the U.S. Food and Drug Administration to help prevent an infectious disease.
Picture: Dr Tristan Vaughan
No comments:
Post a Comment